Top of the morning to you, and a fine one, it is. Once again, clear blue skies and deliciously cool breezes are enveloping the Pharmalot campus as we greet another day. Unfortunately, we can gaze out the window only so long, though. So time to get cracking, as they say. There is much to be done. No doubt you can relate, so here are a few tidbits to help you on your journey, which we hope is a productive and safe one today. Meanwhile, please do keep us in mind if any secret dossiers or saucy tips can be passed along. Have a good one. …

AstraZeneca (AZN) could start profiting from its Covid-19 vaccine as soon as July 2021, according to a memo showing the drug maker can declare when it considers the pandemic to have ended, The Financial Times reports. The company previously said it would not profit from the vaccine “during the pandemic.” The memorandum outlines conditions of a deal signed in July between the drug maker and Fiocruz, a Brazilian public health institution, to produce at least 100 million vaccine doses, worth more than $300 million. The “Pandemic Period” could be extended beyond July 1, 2021, but only if the company “acting in good faith considers that the SARS-CoV-2 pandemic is not over.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy